Solid Biosciences Inc Dossier - Source-backed chat

Solid Biosciences Inc

SLDBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.95

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $6.98Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $748.4M

Shares Outstanding 107.2M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Solid Biosciences is a high-potential, clinical-stage genetic medicine company transitioning into pivotal clinical development. The company's proprietary next-generation capsid, POLARIS-101 (AAV-SLB101), represents a significant technological leap, demonstrating enhanced muscle and cardiac tropism with reduced liver targeting. This addresses the primary safety and efficacy limitations of first-generation gene therapies. With a robust cash position of $380.7 million following a major private placement, Solid has secured an operational runway into the first half of 2028. This runway fully funds key clinical catalysts, including the Phase 3 IMPACT DUCHENNE trial for SGT-003 and initial readouts for SGT-212 in Friedreich's ataxia.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$11.00

Mean target$17.64

High · most bullish analyst$26.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0015%

SGT-003 encounters safety hurdles (such as delayed immune responses or localized inflammation) as patient exposure increases in the Phase 3 trial, or the FDA refuses an accelerated approval pathway, demanding long-term functional endpoints. SGT-212's complex dual-route neurosurgical administration faces enrollment bottlenecks or fails to show meaningful clinical benefit, accelerating cash burn and forcing highly dilutive capital raises before 2028.

Base CaseCentral scenario

$17.6460%

Matches the consensus mean

Solid successfully advances SGT-003 through the Phase 3 IMPACT DUCHENNE trial with steady enrollment and a clean safety profile. Ongoing discussions with the FDA yield a clear, albeit standard, regulatory pathway. SGT-212 and SGT-501 progress through Phase 1b trials on schedule, with initial SGT-212 data by year-end 2026 confirming safety and baseline efficacy. The company's cash runway remains secure into 2028, minimizing near-term dilution risks.

Bull CaseUpside scenario

$26.0025%

SGT-003 demonstrates superior microdystrophin expression and a highly differentiated safety profile (no DILI, TMA, aHUS, or myocarditis) in the Phase 3 IMPACT DUCHENNE trial. The FDA grants accelerated approval based on surrogate biomarker data, positioning SGT-003 as a best-in-class therapy for Duchenne muscular dystrophy. Simultaneously, SGT-212's dual-route administration yields strong frataxin expression in both the brain and heart, validating the platform's multi-system delivery capabilities and attracting lucrative big-pharma partnerships.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Next-Generation Capsid Technology: POLARIS-101 is rationally designed to target integrin receptors, showing enhanced skeletal and cardiac muscle transduction with decreased liver targeting, addressing historical safety concerns of AAV gene therapies.
Strong Balance Sheet: $380.7 million in cash and investments as of Q1 2026 provides an operational runway into H1 2028, protecting the company from near-term capital market volatility.
Diversified Pipeline: Beyond Duchenne (SGT-003), the pipeline includes active clinical programs in Friedreich's ataxia (SGT-212) and CPVT (SGT-501), reducing single-program binary risk.

Key Investment Risks

Clinical and Regulatory Hurdles: Gene therapies face intense regulatory scrutiny; any safety signal (e.g., liver toxicity, myocarditis) could trigger clinical holds.
Neurosurgical Complexity: SGT-212 requires a highly specialized, MRI-guided intradentate nucleus infusion, which could limit patient recruitment and commercial scalability.
Competitive Landscape: The Duchenne space is highly competitive, with established players and other next-generation candidates vying for market share.

Thesis Invalidation Triggers

Occurrence of any severe adverse events (such as drug-induced liver injury, myocarditis, or TMA) in the SGT-003 or SGT-212 clinical trials.
FDA refusal to consider an accelerated approval pathway for SGT-003, significantly delaying potential commercialization timelines.
Significant delays in patient enrollment for the Phase 3 IMPACT DUCHENNE or Phase 1b FALCON trials.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.